Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells

Yidong Li, Yong Mao, Xing-Duo Dong, Zi‐Ning Lei, Yuqi Yang, Lizhu Lin, Charles R. Ashby, Dong‐Hua Yang, Yingfang Fan, Zhe‐Sheng ChenFrontiers in Oncology 2020 · DOI

Abstract

Multidrug resistance (MDR) is a major obstacle in cancer chemotherapy, often driven by the overexpression of efflux transporters like ABCB1 and ABCG2. This study evaluates Methyl-Cantharidimide (MCA), a synthetic analog of cantharidin, as a potential solution. Our results demonstrate that MCA effectively bypasses these transporters and maintains potency in cisplatin-resistant cell lines. MCA's anticancer activity is linked to the induction of apoptosis, G0/G1 phase cell cycle arrest, and the upregulation of the UNC5B death receptor. These findings highlight MCA as a promising candidate for treating drug-resistant malignancies.

Introduction

The efficacy of many chemotherapeutic agents is severely limited by multidrug resistance (MDR). Cancer cells frequently overexpress ATP-binding cassette (ABC) transporters, such as ABCB1 (P-glycoprotein) and ABCG2 (BCRP), which actively pump drugs like paclitaxel out of the cell. Additionally, resistance to DNA-damaging agents like cisplatin further complicates treatment. Cantharidin (CTD), while potent, is highly toxic. This research focuses on Methyl-Cantharidimide (MCA), a modified analog designed to retain anticancer properties while potentially reducing systemic toxicity and overcoming MDR.

Methods

The study utilized a variety of human cancer cell lines and engineered models:

  • Resistance Models: KB-C2 (ABCB1-overexpressing), NCI-H460/MX20 (ABCG2-overexpressing), and cisplatin-resistant BEL-7404/CP20 and KCP-4 cells.
  • Assays: MTT assays determined $IC_{50}$ values; flow cytometry assessed apoptosis and cell cycle distribution; and RNA-sequencing identified differentially expressed genes.

Results and Discussion

Bypassing Efflux Transporters

A critical finding of this study is that MCA is not recognized by the ABCB1 or ABCG2 efflux pumps. While resistant cells were nearly 1000 times less sensitive to paclitaxel, they remained fully sensitive to MCA.

Figure 1: Concentration-dependent viability curves comparing paclitaxel and MCA. Panels A and C show that ABCB1-overexpressing cells (KB-C2 and HEK293/ABCB1) are highly resistant to paclitaxel. Panels B and D demonstrate that MCA maintains consistent efficacy across both parental and resistant cell lines, indicating it is not a substrate for the ABCB1 transporter.

The resistance fold (RF) for MCA in ABCB1-overexpressing cells was approximately 1.17, compared to an RF of 920 for paclitaxel. Similar results were observed in ABCG2-overexpressing models, with MCA $IC_{50}$ values ranging from 6.37 to 9.70 mM regardless of transporter expression.

Efficacy in Cisplatin-Resistant Cells

MCA also demonstrated significant efficacy in cells resistant to cisplatin, such as KCP-4 and BEL-7404/CP20, with $IC_{50}$ values between 7.05 and 8.16 mM. This suggests that MCA's mechanism of action is distinct from that of platinum-based drugs.

Molecular Mechanism: UNC5B and Apoptosis

RNA-seq analysis revealed that MCA treatment significantly upregulates the expression of UNC5B, a p53-regulated death receptor. In BEL-7404 cells, UNC5B expression increased by 5.34-fold. This upregulation correlates with the observed induction of apoptosis and cell cycle arrest in the G0/G1 phase, preventing cancer cell proliferation.

Conclusion

Methyl-Cantharidimide (MCA) effectively targets cancer cells that have developed resistance to conventional chemotherapies by bypassing major efflux pumps and activating apoptotic pathways. While the required millimolar concentrations are high, the ability of MCA to overcome MDR warrants further in vivo investigation to assess its safety and therapeutic potential in clinical settings.

Summary updated

Abstract

In this study, we investigated the efficacy of methyl-cantharidimide (MCA), a cantharidin (CTD) analog, as an anticancer drug, in cancer cells overexpressing either ABCB1 or ABCG2 transporters and in cisplatin-resistant cancer cells. The results indicated that: (i) MCA was efficacious in the ABCB1-overexpressing cell line, KB-C2, and the ABCB1-gene-transfected cell line, HEK293/ABCB1 (IC50 from 6.37 to 8.44 mM); (ii) MCA was also efficacious in the ABCG2-overexpressing cell line, NCI-H460/MX20, and the ABCG2-gene-transfected cell lines, HEK293/ABCG2-482-R2, HEK293/ABCG2-482-G2, and the HEK293/ABCG2-482-T7 cell lines (IC50 from 6.37 to 9.70 mM); (iii) MCA was efficacious in the cisplatin resistant cancer cell lines, KCP-4 and BEL-7404/CP20 (IC50 values from 7.05 to 8.16 mM); (iv) MCA (up to 16 mM) induced apoptosis in both BEL-7404 and BEL-7404/CP20 cancer cells; (v) MCA arrested both BEL-7404 and BEL-7404/CP20 cancer cells in the G0/G1 phase of the cell cycle; (vi) MCA (8 mM) upregulated the expression level of the protein, unc-5 netrin receptor B (UNC5B) in HepG2 and BEL-7404 cancer cells. Overall, our results indicated that MCA's efficacy in ABCB1- and ABCG2-overexpressing and cisplatin resistant cancer cells is due to the induction of apoptosis and cell cycle arrest in the G0/G1 phase.
BibTeX
@inproceedings{li2020methyl,
  author = {Yidong Li and Yong Mao and Xing-Duo Dong and Zi‐Ning Lei and Yuqi Yang and Lizhu Lin and Charles R. Ashby and Dong‐Hua Yang and Yingfang Fan and Zhe‐Sheng Chen},
  title = {{Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.00932},
}
Figure